默克公司的 Clesrovimab (MK-1654) 在婴儿呼吸道合胞病毒预防的 2b/3 期试验中显示出积极结果。 Merck's Clesrovimab (MK-1654) shows positive results in Phase 2b/3 trial for RSV prevention in infants.
默克公司宣布呼吸道合胞病毒预防性单克隆抗体 Clesrovimab (MK-1654) 的 2b/3 期试验取得了积极结果，该药物可以减少婴儿下呼吸道感染的发生。 Merck announces positive Phase 2b/3 trial results for RSV preventative monoclonal antibody, Clesrovimab (MK-1654), reducing medically attended lower respiratory infections in infants. 呼吸道合胞病毒 (RSV) 传染性极强，是导致婴儿住院的主要原因，并给全球带来了沉重的负担。 The highly contagious RSV is a leading cause of infant hospitalization and has a significant global burden. 默克公司计划向全球监管机构提交详细研究结果和文件数据，旨在为 RSV 对婴儿和家庭的影响提供新的选择。 Merck plans to present detailed findings and file data with global regulators, aiming to provide a new option for RSV impact on infants and families.